Department of Obstetrics and Gynecology, King Faisal Specialist Hospital and Research Center, Jeddah, Saudi Arabia.
Department of Obstetrics and Gynecology, Maternity and Children Hospital, AlKharj, Saudi Arabia.
Eur J Obstet Gynecol Reprod Biol. 2023 Dec;291:112-119. doi: 10.1016/j.ejogrb.2023.10.011. Epub 2023 Oct 12.
To investigate the efficacy of vaginal probiotics administration in combination with prophylactic antibiotics versus antibiotic prophylaxis only on perinatal outcomes in women with preterm premature rupture of membrane (PPROM).
Four different databases were searched from inception till March 2023. We selected randomized controlled trials (RCTs) that compared vaginal probiotics along with antibiotics versus antibiotics only among pregnant women who were presented with PPROM between 24 and 34 weeks of gestation. We performed the meta-analysis using Revman software. Our primary outcomes were gestational age at birth and latency period duration. Our secondary outcomes were the rate of admission in the neonatal intensive care unit (NICU), infant birth weight, length of stay in the NICU, and neonatal complications.
Four RCTs, involving a total of 339 patients, were included in the meta-analysis. The gestational age at the time of delivery and latency period duration were significantly higher among probiotics + antibiotics group (p = 0.01 & p < 0.001). There was a significant reduction in the rate of NICU admission and length of NICU stay among the probiotics + antibiotics group compared to the antibiotics only group. A significant improvement in the infant birth weight after delivery was demonstrated among the probiotics + antibiotics group (p = 0.002). Although there was a decrease in the incidence of neonatal sepsis and respiratory distress syndrome within probiotics + antibiotics group versus antibiotics only group, these differences were not statistically significant (p > 0.05).
The combination of vaginal probiotics and antibiotic prophylaxis has been shown to effectively improve perinatal outcomes in women with PPROM. Further trials are needed to validate our findings.
探讨阴道益生菌联合预防性抗生素与仅用抗生素预防在胎膜早破(PPROM)孕妇围产结局中的疗效。
从建库到 2023 年 3 月,我们检索了 4 个不同的数据库。我们选择了比较阴道益生菌联合抗生素与仅用抗生素预防在妊娠 24-34 周出现 PPROM 的孕妇的随机对照试验(RCT)。我们使用 RevMan 软件进行荟萃分析。我们的主要结局是出生时的胎龄和潜伏期持续时间。我们的次要结局是新生儿重症监护病房(NICU)入院率、婴儿出生体重、NICU 住院时间和新生儿并发症。
纳入的 4 项 RCT 共 339 例患者,进行了荟萃分析。与仅用抗生素组相比,益生菌+抗生素组的分娩时胎龄和潜伏期持续时间显著更高(p=0.01 和 p<0.001)。与仅用抗生素组相比,益生菌+抗生素组的 NICU 入院率和 NICU 住院时间显著降低。与仅用抗生素组相比,益生菌+抗生素组婴儿出生体重显著增加(p=0.002)。虽然益生菌+抗生素组新生儿败血症和呼吸窘迫综合征的发生率有所降低,但这些差异无统计学意义(p>0.05)。
阴道益生菌联合抗生素预防可有效改善 PPROM 孕妇的围产结局。需要进一步的试验来验证我们的发现。